{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:36:41Z","timestamp":1792816601568,"version":"4.5.0"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vera Therapeutics., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immunoglobulin A nephropathy (IgAN) is an immune-mediated disease of B-cell origin and the most common primary glomerulonephritis worldwide, which often progresses to kidney failure within 10\u201320 years of diagnosis. Microscopic hematuria is frequently observed in IgAN; it is thought to result from damage to the glomerular filtration barrier caused by pathogenic immune complex deposits, allowing red blood cells to leak into the urinary space. Emerging evidence suggests that microscopic hematuria in IgAN may be linked to active glomerular inflammation, poorer disease prognosis and progressive kidney function decline. Despite this, it remains an underutilized biomarker for IgAN because of a lack of standardization (which can lead to preanalytical errors), challenging logistical considerations in large multicenter trials and non-glomerular hematuria as a confounding factor. The \u201cproteinuria-centric\u201d approach by the nephrology community may overlook that active forms of glomerulonephritis manifest with both proteinuria and hematuria, in contrast to primary podocytopathies where proteinuria is the main feature. When properly assessed, microscopic hematuria is a prognostically relevant biomarker in IgAN that may improve risk stratification and assessment of therapeutic response when evaluated alongside traditional biomarkers. This review evaluates the methods of assessment, pathophysiology and clinical utility of microscopic hematuria in IgAN.<\/jats:p>","DOI":"10.1093\/ckj\/sfag003","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:35:33Z","timestamp":1768048533000},"source":"Crossref","is-referenced-by-count":16,"title":["Microscopic hematuria in IgA nephropathy: a biomarker of disease activity"],"prefix":"10.1093","volume":"19","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[{"name":"Division of Nephrology and Rheumatology, RWTH Aachen University Hospital , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-6282","authenticated-orcid":false,"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[{"name":"Fondazione Ricerca Molinette , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026021603564764200_bib1","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy","volume":"28","author":"Sevillano","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"2026021603564764200_bib3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life expectancy for patients from the southeastern United States with IgA nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026021603564764200_bib5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"2026021603564764200_bib6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/001c.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"2026021603564764200_bib7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021603564764200_bib8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.34067\/KID.0000000000000165","article-title":"Global incidence of IgA nephropathy by race and ethnicity: a systematic review","volume":"4","author":"Kiryluk","year":"2023","journal-title":"Kidney360"},{"key":"2026021603564764200_bib9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2310\/JIM.0b013e3181d20aa1","article-title":"Clinicopathological characteristics and prognostic factors of asymptomatic IgA nephropathy","volume":"58","author":"Shen","year":"2010","journal-title":"J Investig Med"},{"issue":"Suppl","key":"2026021603564764200_bib10","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib11","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1681\/ASN.2017060639","article-title":"Persistent Microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker","volume":"28","author":"Coppo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib12","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMra020109","article-title":"IgA nephropathy","volume":"347","author":"Donadio","year":"2002","journal-title":"N Engl J Med"},{"key":"2026021603564764200_bib13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/ndt\/gfz267","article-title":"The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy","volume":"36","author":"Bobart","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026021603564764200_bib14","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3390\/ijms20092205","article-title":"Glomerular hematuria: cause or consequence of renal inflammation?","volume":"20","author":"Moreno","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026021603564764200_bib15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jama.2011.1141","article-title":"Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease","volume":"306","author":"Vivante","year":"2011","journal-title":"JAMA"},{"key":"2026021603564764200_bib16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.7861\/clinmedicine.15-6-576","article-title":"Isolated microscopic haematuria of glomerular origin: clinical significance and diagnosis in the 21st century","volume":"15","author":"Chan","year":"2015","journal-title":"Clin Med"},{"key":"2026021603564764200_bib17","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026021603564764200_bib18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.emc.2019.07.011","article-title":"The approach to the patient with hematuria","volume":"37","author":"Willis","year":"2019","journal-title":"Emerg Med Clin North Am"},{"key":"2026021603564764200_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/JU.0000000000004490","article-title":"Updates to microhematuria: AUA\/SUFU guideline (2025)","volume":"213","author":"Barocas","year":"2025","journal-title":"J Urol"},{"key":"2026021603564764200_bib20","volume-title":"Gross and Microscopic Hematuria","author":"Leslie","year":"2025"},{"issue":"4S","key":"2026021603564764200_bib21","first-page":"S1","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/BLC-160068","article-title":"Dipstick urinalysis as a test for microhematuria and occult bladder cancer","volume":"3","author":"Matulewicz","year":"2017","journal-title":"ladder Cancer"},{"key":"2026021603564764200_bib23","first-page":"27","article-title":"Office-based urinalysis: a comprehensive review","volume":"106","author":"Hitzeman","year":"2022","journal-title":"Am Fam Physician"},{"key":"2026021603564764200_bib24","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1515\/cclm-2023-0260","article-title":"Pitfalls in the diagnosis of hematuria","volume":"61","author":"Delanghe","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"2026021603564764200_bib25","doi-asserted-by":"publisher","first-page":"e22870","DOI":"10.1002\/jcla.22870","article-title":"Semiquantitative, fully automated urine test strip analysis","volume":"33","author":"Oyaert","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"2026021603564764200_bib26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000529650","article-title":"Clinical Significance of persistent hematuria degrees in primary IgA nephropathy: a propensity score-matched analysis of a 10-year follow-up cohort","volume":"54","author":"Huang","year":"2023","journal-title":"Am J Nephrol"},{"key":"2026021603564764200_bib27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40620-021-01064-4","article-title":"Pre-treatment hematuria and crescents predict estimated glomerular filtration rate trajectory after methylprednisolone pulse therapy with tonsillectomy for IgA nephropathy","volume":"35","author":"Nagai","year":"2022","journal-title":"J Nephrol"},{"key":"2026021603564764200_bib28","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/ndt\/gfn610","article-title":"Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm","volume":"24","author":"Goto","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2026021603564764200_bib29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","article-title":"Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study","volume":"76","author":"Yu","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026021603564764200_bib30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/UPJ.0000000000000083","article-title":"Automated urinalysis for evaluation of microscopic hematuria: current options and revising the gold standard","volume":"7","author":"Hertz","year":"2020","journal-title":"Urol Pract"},{"key":"2026021603564764200_bib31","article-title":"Urinalysis","volume-title":"StatPearls [Internet]","author":"Milani","year":"2023"},{"key":"2026021603564764200_bib32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.11613\/BM.2016.008","article-title":"Evaluation of the appropriate time period between sampling and analyzing for automated urinalysis","volume":"26","author":"Dolscheid-Pommerich","year":"2016","journal-title":"Biochem Med"},{"key":"2026021603564764200_bib33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12882-024-03933-z","article-title":"Changes in the composition of urine over six hours using urine dipstick analysis and automated microscopy","volume":"26","author":"Parikh","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026021603564764200_bib34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021603564764200_bib35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510198","article-title":"A Phase 3 trial of atacicept in patients with IgA nephropathy","author":"Lafayette","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021603564764200_bib36","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s10157-021-02069-w","article-title":"Utility of remission criteria for the renal prognosis of IgA nephropathy","volume":"25","author":"Matsuzaki","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2026021603564764200_bib37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1542\/pir.2017-0300","article-title":"Hematuria and proteinuria in children","volume":"39","author":"Viteri","year":"2018","journal-title":"Pediatr Rev"},{"key":"2026021603564764200_bib38","doi-asserted-by":"publisher","first-page":"e0128575","DOI":"10.1371\/journal.pone.0128575","article-title":"Haematuria increases progression of advanced proteinuric kidney disease","volume":"10","author":"Yuste","year":"2015","journal-title":"PLoS One"},{"key":"2026021603564764200_bib39","article-title":"Physiology, Renal Blood Flow and Filtration. [Updated 2023 Jul 24]. StatPearls [Internet]","author":"Dalal","year":"2025"},{"key":"2026021603564764200_bib40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAP.0000000000000134","article-title":"Pathophysiology of IgA nephropathy","volume":"24","author":"Al Hussain","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"2026021603564764200_bib41","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/ndt\/17.9.1586","article-title":"Glomerular changes in microscopic haematuria, studied by quantitative immunoelectron microscopy and in situ zymography","volume":"17","author":"Jalalah","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2026021603564764200_bib42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ki.2013.284","article-title":"The role of the kidney in protein metabolism: the capacity of tubular lysosomal proteolysis in nephrotic syndrome","volume":"84","author":"Tojo","year":"2013","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib43","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","article-title":"Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy","volume":"18","author":"Suzuki","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2026021603564764200_bib44","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.3390\/jcm12216927","article-title":"A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J Clin Med"},{"key":"2026021603564764200_bib45","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1681\/ASN.2019040373","article-title":"Fatal attraction: immunoglobulin A and the glomerular mesangium","volume":"30","author":"Floege","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fimmu.2016.00117","article-title":"The origin and activities of IgA1-containing immune complexes in IgA nephropathy","volume":"7","author":"Knoppova","year":"2016","journal-title":"Front Immunol"},{"key":"2026021603564764200_bib47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000319124","article-title":"Prospects and perspectives on IgA nephropathy from animal models","volume":"169","author":"Emancipator","year":"2011","journal-title":"Contrib Nephrol"},{"key":"2026021603564764200_bib48","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1681\/ASN.2015080856","article-title":"IgA1 protease treatment reverses mesangial deposits and hematuria in a model of IgA nephropathy","volume":"27","author":"Lechner","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib49","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: the lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/ki.2012.160","article-title":"In search of a better understanding of IgA nephropathy-associated hematuria","volume":"82","author":"Eitner","year":"2012","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib51","doi-asserted-by":"publisher","first-page":"753506","DOI":"10.3389\/fmed.2021.753506","article-title":"Chronic hematuria increases chronic kidney injury and epithelial-mesenchymal transition in 5\/6 nephrectomy rats","volume":"8","author":"Xiao","year":"2021","journal-title":"Front Med"},{"key":"2026021603564764200_bib52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0272-6386(12)80312-X","article-title":"Tubulointerstitial changes as a major determinant in the progression of renal damage","volume":"20","author":"Nath","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"2026021603564764200_bib53","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1046\/j.1523-1755.2000.00101.x","article-title":"Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult","volume":"57","author":"Nath","year":"2000","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib54","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa307","article-title":"Urine proteomics for prediction of disease progression in patients with IgA nephropathy","volume":"37","author":"Rudnicki","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026021603564764200_bib55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.15171\/jnp.2016.12","article-title":"Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuria","volume":"5","author":"Iwasaki","year":"2016","journal-title":"J Nephropathol"},{"key":"2026021603564764200_bib56","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s10157-014-1068-9","article-title":"Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria","volume":"19","author":"Tanaka","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"2026021603564764200_bib57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1159\/000525001","article-title":"Long-term outcomes of patients with IgA nephropathy categorized by the international IgAN risk prediction tool and by the degree of hematuria at diagnosis","volume":"146","author":"Ebbestad","year":"2022","journal-title":"Nephron"},{"key":"2026021603564764200_bib58","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.3390\/jcm11226785","article-title":"Time-averaged hematuria as a prognostic indicator of renal outcome in patients with IgA nephropathy","volume":"11","author":"Weng","year":"2022","journal-title":"J Clin Med"},{"key":"2026021603564764200_bib59","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/0886022X.2021.1879852","article-title":"Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis","volume":"43","author":"He","year":"2021","journal-title":"Ren Fail"},{"key":"2026021603564764200_bib60","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40620-020-00725-0","article-title":"IgA nephropathy in children and in adults: two separate entities or the same disease?","volume":"33","author":"Coppo","year":"2020","journal-title":"J Nephrol"},{"key":"2026021603564764200_bib61","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/path.5011","article-title":"Podocytes are new cellular targets of haemoglobin-mediated renal damage","volume":"244","author":"Rubio-Navarro","year":"2018","journal-title":"J Pathol"},{"key":"2026021603564764200_bib62","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.kint.2023.02.029","article-title":"Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis","volume":"103","author":"Benichou","year":"2023","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000500352","article-title":"Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis","volume":"49","author":"Vandenbussche","year":"2019","journal-title":"Am J Nephrol"},{"key":"2026021603564764200_bib64","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021603564764200_bib65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","article-title":"Lupus nephritis: redefining the treatment goals","volume":"107","author":"De Vriese","year":"2025","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40364-024-00619-4","article-title":"Blood and urine biomarkers of disease progression in IgA nephropathy","volume":"12","author":"Duan","year":"2024","journal-title":"Biomark Res"},{"key":"2026021603564764200_bib67","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1016\/j.ekir.2023.09.020","article-title":"Evaluating progression risk in patients with immunoglobulin a nephropathy","volume":"8","author":"Cattran","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026021603564764200_bib68","doi-asserted-by":"publisher","first-page":"1148553","DOI":"10.3389\/fphar.2023.1148553","article-title":"Podocytes are likely the therapeutic target of IgA nephropathy with isolated hematuria: evidence from repeat renal biopsy","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026021603564764200_bib69","doi-asserted-by":"publisher","first-page":"572754","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"2026021603564764200_bib70","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021603564764200_bib72","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.34067\/KID.0000000583","article-title":"Efficacy and safety of nefecon in patients with IgA nephropathy from mainland China: 2-year NefIgArd trial results","volume":"5","author":"Zhang","year":"2024","journal-title":"Kidney360"},{"key":"2026021603564764200_bib73","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib74","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/j.ekir.2024.02.322","article-title":"Wcn24-1294 Atacicept reduces hematuria and serum Gd-IgA1, both associated with long-term renal outcomes in IgA nephropathy: 36-week results from the phase 2b ORIGIN study","volume":"9","author":"Barratt","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"Suppl_1","key":"2026021603564764200_bib75","doi-asserted-by":"publisher","first-page":"i710","DOI":"10.1093\/ndt\/gfae069.432","article-title":"Impact of atacicept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study","volume":"39","author":"Floege","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026021603564764200_bib76","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib77","first-page":"10.1681","article-title":"Results from longer follow-up with povetacicept, an enhanced dual BAFF\/APRIL antagonist, in IgA nephropathy (RUBY-3 study): FR-PO854","volume":"35","author":"Madan","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026021603564764200_bib78","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.ekir.2024.02.258","article-title":"Hematuria resolution with the APRIL-blocking monoclonal antibody, sibeprenlimab, in patients with IgA nephropathy in a phase 2 randomized controlled trial","volume":"9","author":"Barratt","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026021603564764200_bib79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021603564764200_bib80","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a Phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"2026021603564764200_bib81","doi-asserted-by":"publisher","first-page":"1242241","DOI":"10.3389\/fmed.2023.1242241","article-title":"Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy","volume":"10","author":"Dong","year":"2023","journal-title":"Front Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag003\/66358327\/sfag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag003\/66358327\/sfag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag003\/66358327\/sfag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:56:53Z","timestamp":1771232213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag003\/8422522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag003","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,12]]},"article-number":"sfag003"}}